ArticleJournal of virology2009
Baculovirus transduction of mesenchymal stem cells triggers the toll-like receptor 3 pathway.
Article in Journal of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 60 citations in OpenAlex.
- Application of BMP-2 and its gene delivery vehicles in dentistry.The Saudi dental journal · 2024Review
- Critical roles of TLRs on the polarization of mesenchymal stem cells for cell therapy of viral infections: a notice for COVID-19 treatment.Comparative clinical pathology · 2021Article
- Bidirectional and Opposite Effects of Naïve Mesenchymal Stem Cells on Tumor Growth and Progression.Advanced pharmaceutical bulletin · 2019Review
- BMP-2 Gene Delivery-Based Bone Regeneration in Dentistry.Pharmaceutics · 2019Review
- Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8Journal of microbiology (Seoul, Korea) · 2017Article
- Global Screening of Antiviral Genes that Suppress Baculovirus Transgene Expression in Mammalian Cells.Molecular therapy. Methods & clinical development · 2017Article
- Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review.Immune network · 2017Review
- Cell Expansion-Dependent Inflammatory and Metabolic Profile of Human Bone Marrow Mesenchymal Stem Cells.Frontiers in physiology · 2016Article
- Respiratory Syncytial Virus-Infected Mesenchymal Stem Cells Regulate Immunity via Interferon Beta and Indoleamine-2,3-Dioxygenase.PloS one · 2016Article
- Review
- The TLR7 agonist Imiquimod promote the immunogenicity of mesenchymal stem cells.Biological research · 2015Article
- Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells.Journal of virology · 2014Article
- Regenerating cartilages by engineered ASCs: prolonged TGF-β3/BMP-6 expression improved articular cartilage formation and restored zonal structure.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Adaptive immune responses elicited by baculovirus and impacts on subsequent transgene expression in vivo.Journal of virology · 2013Article
- Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency.American journal of physiology. Cell physiology · 2012Article
- Development of the hybrid Sleeping Beauty: baculovirus vector for sustained gene expression and cancer therapy.Gene therapy · 2012Article
- Defective antiviral responses of induced pluripotent stem cells to baculoviral vector transduction.Journal of virology · 2012Article
- Induction of antigen-specific immune responses in mice by recombinant baculovirus expressing premembrane and envelope proteins of West Nile virus.Virology journal · 2012Article
- Toll-like receptors as modulators of mesenchymal stem cells.Frontiers in immunology · 2012Article
- Norkurarinol inhibits toll-like receptor 3 (TLR3)-mediated pro-inflammatory signaling pathway and rotavirus replication.Journal of pharmacological sciences · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human mesenchymal stem cells (hMSCs) can be genetically modified with viral vectors and hold promise as a cell source for regenerative medicine, yet how hMSCs respond to viral vector transduction remains poorly understood, leaving the safety concerns unaddressed. Here, we explored the responses of hMSCs against an emerging DNA viral vector, baculovirus (BV), and discovered that BV transduction perturbed the transcription of 816 genes associated with five signaling pathways. Surprisingly, Toll-like receptor-3 (TLR3), a receptor that generally recognizes double-stranded RNA, was apparently upregulated by BV transduction, as confirmed by microarray, PCR array, flow cytometry, and confocal microscopy. Cytokine array data showed that BV transduction triggered robust secretion of interleukin-6 (IL-6) and IL-8 but not of other inflammatory cytokines and beta interferon (IFN-beta). BV transduction activated the signaling molecules (e.g., Toll/interleukin-1 receptor domain-containing adaptor-inducing IFN-beta, NF-kappaB, and IFN regulatory factor 3) downstream of TLR3, while silencing the TLR3 gene with small interfering RNA considerably abolished cytokine expression and promoted cell migration. These data demonstrate, for the first time, that a DNA viral vector can activate the TLR3 pathway in hMSCs and lead to a cytokine expression profile distinct from that in immune cells. These findings underscore the importance of evaluating whether the TLR3 signaling cascade plays roles in the immune response provoked by other DNA vectors (e.g., adenovirus). Nonetheless, BV transduction barely disturbed surface marker expression and induced only transient and mild cytokine responses, thereby easing the safety concerns of using BV for hMSCs engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.